Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Board

Company Overview

Team

Values

Clinical Advisers

Corporate Directory

Corporate Governance

About Us

Presentations

In the News

Video Updates

Communication

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Clinical Trial

Home

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

Amplia today announced that it has received new grant funding to support a research collaboration with CSIRO to develop formulations of its FAK inhibitors for topical application.

With the funding, provided through Innovation Connections, Amplia will work with researchers at CSIRO to help develop formulations that could be applied topically to wounds and burns which may aid healing and reduce scarring.

Amplia’s CEO and Managing Director Dr Chris Burns commented:

“There is growing evidence in the scientific literature that inhibition of FAK in the skin may accelerate wound healing and limit scar formation. We are looking forward to working with CSIRO to develop a formulation of our proprietary FAK inhibitors so we can determine their suitability for use in wound healing.”

The global wound healing market is estimated to be in excess US$20b and the market for scar treatments is of similar size.

Click link below to read the full ASX Release.

Amplia receives grant to collaborate with CSIRO